Sterling Biotech Ltd Stock Analysis

BSE: 512299 | NSE: STERLINBIO | Chemicals | Small Cap

BSE Share Price
Not Listed

DeciZen - Make an Informed Decision on Sterling Biotech

M-Cap below 100cr DeciZen not available

Sterling Biotech Price Chart

P/E Ratio ( SA) :
0.00
Market Cap :
21 Cr.
52-wk low :
0.8
52-wk high :
0.9
Bole Toh?

1. Is Sterling Biotech Ltd. a good quality company?

Data is not available for this company.

2. Is Sterling Biotech Ltd. undervalued or overvalued?

No data found

3. Is Sterling Biotech Ltd. a good buy now?

No data found

10 Year X-Ray of Sterling Biotech:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.

Value Creation

Value Creation Index Colour Code Guide

Dec'08Dec'09Dec'10Dec'11Dec'12Dec'13Dec'14Mar'16Mar'17Mar'18TTM
ROCE % 7%6.2%6.2%4.3%-1%-1.7%-2.1%-2.1%-1.9%-2%-
Value Creation Index -0.5-0.6-0.6-0.7-1.1-1.1-1.2-1.2-1.1-1.1-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 1,1781,4381,6171,662835718667419368352408
YoY Gr. Rt. %-22.1%12.4%2.8%-49.8%-14%-7.1%-37.2%-12.1%-4.4%-
Adj EPS 9.27.77.13.2-13-15-16.8-13.2-15.2-17.1-10.9
YoY Gr. Rt. %--16.8%-7.8%-54.3%-503.4%NANANANANA-
BVPS (₹) 69.982.2929369.854.938.148.946.910.1-79.7
Adj Net Profit 22819219086.5-349-401-458-360-412-465-295
Cash Flow from Ops. -98.7-1.334837081117225653.61-32.8-
Debt/CF from Ops. -27.1-2339.610.811.54.522.618987326.3-228.4-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales -12.6%-15.9%-19.2%-4.4%
Adj EPS -207.1%NANANA
BVPS -19.3-32-35.7-78.4
Share Price - - - -

Key Financial Parameters

Performance Ratio Colour Code Guide

Dec'08Dec'09Dec'10Dec'11Dec'12Dec'13Dec'14Mar'16Mar'17Mar'18TTM
Return on Equity % 15.110.18.43.5-16-24-22.8-21.4-28.1-59.931.2
Op. Profit Mgn % 42.535.243.138.417.713.21212.33.449
Net Profit Mgn % 19.413.311.75.2-41.8-55.8-68.6-86-112-131.9-72.4
Debt to Equity 1.61.51.51.71.92.61.845.527.2-
Working Cap Days 3053764214588017427247911,0978530
Cash Conv. Cycle 1872322713256305865245046694270

Recent Performance Summary

No data to display

Return on Equity has declined versus last 3 years average to %

Sales growth has been subdued in last 3 years %

Sales growth is not so good in last 4 quarters at %

Latest Financials - Sterling Biotech Ltd.

Standalone Consolidated
TTM EPS (₹) -10.9 -
TTM Sales (₹ Cr.) 408 -
BVPS (₹.) -79.7 -
Reserves (₹ Cr.) -2,197 -
P/BV -0.01 -
PE 0.00 -
From the Market
52 Week Low / High (₹) 0.77 / 0.85
All Time Low / High (₹) 0.67 / 262.45
Market Cap (₹ Cr.) 21
Equity (₹ Cr.) 27.2
Face Value (₹) 1
Industry PE 29.8

Management X-Ray of Sterling Biotech :

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *62.2962.2962.2962.2962.2962.2962.2962.2962.2962.29
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Sterling Biotech

Adj EPS (Rs.)
Sales (Cr.)
ROE (%)
ROCE (%)

News

Sterling Biotech Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Sterling Biotech on 01-Jan-1970 05:30 is : 0.00.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 01-Jan-1970 05:30 the market cap of Sterling Biotech stood at ₹ 20.96.
The latest PE ratio of Sterling Biotech as of 01-Jan-1970 05:30 is 0.00.
The latest PB ratio of Sterling Biotech as of 01-Jan-1970 05:30 is -0.01
The 52-week high of Sterling Biotech is ₹ 0.85 and the 52-week low is ₹ 0.77.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue / sales of Sterling Biotech is ₹ 408.1 ( Cr.) .

About Sterling Biotech Ltd

Working with and developing any opportunity into reality is a mindset at Sterling Group. Sterling Biotech Limited with its new thinking, new capabilities and sense of urgency aspires to “Earn trust, every moment” of its partners, collaborators, stake holders and customers.

The company is focusing to commercialize Active Pharmaceutical Ingredient (API) and make it available at competitive prices to its global customers.

The company’s capabilities include state of art research centre, advance pilot plant for scale up studies, modern facility of bioreactors and range of down streaming process equipments. All these are coupled with dedicated and qualified work force, well equipped quality control laboratory and quality assurance systems

The company strives to become leaders in API pharmaceutical area by developing state of the art facility for research and development, contract manufacturing of active pharmaceutical ingredients. It builds quality in every aspect of manufacturing with particular laid down emphasis based on current Good Manufacturing Practices.

The company is committed to scaling new heights and creating new dimensions in Fermentation based API and Synthetic API. This way it shall support aspiration to “Live better and Live longer”.

The company’s manufacturing facility at Masar, Gujarat, is at par with international standards. It complies with cGMP norms complying to the standards of WHO and is in the process of getting CEP for the active pharmaceutical ingredient Epirubicin, Lovastatin

This adequately reflects Sterlings commitment towards quality. Efforts to attain such standards have also opened the key to gain foothold in the regulated and semi regulated markets throughout US and Europe

Business area of the company

The company is engaged in the manufacturing of Pharma Grade Gelatine & Di-Calcium Phosphate and other Pharma products. The Company has presence in both domestic and international markets.

Products

  • Simvastatin Ammonium Salt
  • Lovastatin
  • Daunorubicin HCL
  • Doxorubicin HCL
  • Epirubicin HCL
  • Idarubicin HCL
  • Zoledronic Acid
Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now